JP2019527194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527194A5 JP2019527194A5 JP2018563050A JP2018563050A JP2019527194A5 JP 2019527194 A5 JP2019527194 A5 JP 2019527194A5 JP 2018563050 A JP2018563050 A JP 2018563050A JP 2018563050 A JP2018563050 A JP 2018563050A JP 2019527194 A5 JP2019527194 A5 JP 2019527194A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 82
- 239000012634 fragment Substances 0.000 claims description 81
- 239000000427 antigen Substances 0.000 claims description 77
- 102000036639 antigens Human genes 0.000 claims description 77
- 108091007433 antigens Proteins 0.000 claims description 77
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 18
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 9
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 208000032859 Synucleinopathies Diseases 0.000 claims description 7
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 6
- 201000002832 Lewy body dementia Diseases 0.000 claims description 6
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 101000787265 Homo sapiens Beta-synuclein Proteins 0.000 claims description 3
- 101000787273 Homo sapiens Gamma-synuclein Proteins 0.000 claims description 3
- 101000834885 Macaca fascicularis Alpha-synuclein Proteins 0.000 claims description 3
- 101000834882 Rattus norvegicus Alpha-synuclein Proteins 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 101150110503 END3 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022082099A JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
| JP2024103562A JP2024123247A (ja) | 2016-06-02 | 2024-06-27 | α－シヌクレインに対する抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344746P | 2016-06-02 | 2016-06-02 | |
| US62/344,746 | 2016-06-02 | ||
| PCT/EP2017/063406 WO2017207739A1 (en) | 2016-06-02 | 2017-06-01 | Antibodies to alpha-synuclein and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082099A Division JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527194A JP2019527194A (ja) | 2019-09-26 |
| JP2019527194A5 true JP2019527194A5 (OSRAM) | 2020-07-09 |
| JP7078552B2 JP7078552B2 (ja) | 2022-05-31 |
Family
ID=59021492
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563050A Active JP7078552B2 (ja) | 2016-06-02 | 2017-06-01 | α－シヌクレインに対する抗体およびその使用 |
| JP2022082099A Pending JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
| JP2024103562A Pending JP2024123247A (ja) | 2016-06-02 | 2024-06-27 | α－シヌクレインに対する抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082099A Pending JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
| JP2024103562A Pending JP2024123247A (ja) | 2016-06-02 | 2024-06-27 | α－シヌクレインに対する抗体およびその使用 |
Country Status (38)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| CN110072888B (zh) | 2016-12-16 | 2023-07-18 | H.隆德贝克有限公司 | 药剂、用途和方法 |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EP3583124A1 (en) | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| BR112021006123A2 (pt) * | 2018-10-19 | 2021-07-20 | Janssen Vaccines & Prevention B.V. | anticorpos anti-sinucleína |
| TWI734279B (zh) | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| KR20210154179A (ko) | 2019-04-18 | 2021-12-20 | 에이씨 이뮨 에스.에이. | 치료 및 진단용 신규한 분자 |
| CN110172098B (zh) * | 2019-05-27 | 2023-03-10 | 长春工业大学 | 抗α-突触核蛋白的单克隆抗体及其应用 |
| AU2020350769A1 (en) | 2019-09-20 | 2022-03-31 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| KR102239512B1 (ko) * | 2020-09-10 | 2021-04-12 | 서울대학교산학협력단 | 다중기능성 마이크로캡슐 조성물 및 그 제조방법 |
| EP4229082A1 (en) | 2020-10-16 | 2023-08-23 | AC Immune SA | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| CN112920274A (zh) * | 2021-03-17 | 2021-06-08 | 江苏贝格尔生物医药有限公司 | 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用 |
| CN113912716B (zh) * | 2021-12-15 | 2022-03-01 | 北京凯祥弘康生物科技有限公司 | 针对α-突触核蛋白抗原的抗体及其应用 |
| WO2024141576A1 (en) | 2022-12-29 | 2024-07-04 | Astrazeneca Ab | Compositions and methods for treating alpha-synucleinopathies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| HUE035044T2 (en) | 2003-05-19 | 2018-05-02 | Prothena Biosciences Ltd | Truncated fragments of alpha-synuclein in Lewy-body disease |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| US20090233357A1 (en) | 2005-09-27 | 2009-09-17 | Abedelnasser Abulrob | Targeted Delivery of Compounds Using Multimerization Technology |
| JP5558834B2 (ja) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| JP4934074B2 (ja) | 2007-03-07 | 2012-05-16 | 株式会社アルファ | スイッチ固定構造 |
| LT2282758T (lt) | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
| CA2746778C (en) | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
| JP4654348B1 (ja) | 2010-02-23 | 2011-03-16 | 多摩川精機株式会社 | 検出装置用巻線の正弦波巻線方法 |
| CN102869680B (zh) | 2010-02-26 | 2016-10-05 | 生命北极神经科学公司 | 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用 |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| BR112014010198B1 (pt) | 2011-10-28 | 2022-12-06 | Prothena Biosciences Limited | Anticorpos humanizados que reconhecem alfa-sinucleína |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| SI3071597T1 (sl) * | 2013-11-21 | 2020-11-30 | F. Hoffmann-La Roche Ag | Anti alfa-sinukleinska protitelesa in postopki uporabe |
| PT3218406T (pt) | 2014-11-10 | 2021-06-17 | Medimmune Ltd | Moléculas de ligação específicas para cd73 e seus usos |
-
2017
- 2017-06-01 TW TW111117603A patent/TW202309093A/zh unknown
- 2017-06-01 WO PCT/EP2017/063406 patent/WO2017207739A1/en not_active Ceased
- 2017-06-01 SG SG11201810420YA patent/SG11201810420YA/en unknown
- 2017-06-01 NZ NZ748616A patent/NZ748616A/en unknown
- 2017-06-01 EP EP21202106.7A patent/EP4000632A1/en active Pending
- 2017-06-01 HU HUE17728525A patent/HUE057214T2/hu unknown
- 2017-06-01 UA UAA201811679A patent/UA124733C2/uk unknown
- 2017-06-01 JP JP2018563050A patent/JP7078552B2/ja active Active
- 2017-06-01 KR KR1020187037675A patent/KR102499438B1/ko active Active
- 2017-06-01 AU AU2017272804A patent/AU2017272804B2/en active Active
- 2017-06-01 SM SM20220008T patent/SMT202200008T1/it unknown
- 2017-06-01 PT PT177285251T patent/PT3463435T/pt unknown
- 2017-06-01 TW TW106118078A patent/TWI765890B/zh active
- 2017-06-01 MX MX2018014456A patent/MX393740B/es unknown
- 2017-06-01 SI SI201731025T patent/SI3463435T1/sl unknown
- 2017-06-01 MD MDE20190406T patent/MD3463435T2/ro unknown
- 2017-06-01 LT LTEPPCT/EP2017/063406T patent/LT3463435T/lt unknown
- 2017-06-01 MA MA45125A patent/MA45125B1/fr unknown
- 2017-06-01 RS RS20211502A patent/RS62682B1/sr unknown
- 2017-06-01 CN CN201780045951.2A patent/CN109475616B/zh active Active
- 2017-06-01 ES ES17728525T patent/ES2903402T3/es active Active
- 2017-06-01 MY MYPI2018002168A patent/MY188183A/en unknown
- 2017-06-01 DK DK17728525.1T patent/DK3463435T3/da active
- 2017-06-01 PE PE2023002924A patent/PE20250392A1/es unknown
- 2017-06-01 AR ARP170101504A patent/AR108663A1/es unknown
- 2017-06-01 CA CA3025987A patent/CA3025987A1/en active Pending
- 2017-06-01 EA EA202191380A patent/EA202191380A1/ru unknown
- 2017-06-01 EP EP17728525.1A patent/EP3463435B1/en active Active
- 2017-06-01 EA EA201892548A patent/EA038358B1/ru unknown
- 2017-06-01 CN CN202211223767.1A patent/CN116120445A/zh active Pending
- 2017-06-01 HR HRP20211935TT patent/HRP20211935T1/hr unknown
- 2017-06-01 PL PL17728525T patent/PL3463435T3/pl unknown
- 2017-06-01 GE GEAP201714964A patent/GEP20217253B/en unknown
- 2017-06-01 PE PE2018003155A patent/PE20190440A1/es unknown
- 2017-06-01 BR BR112018074978-8A patent/BR112018074978A2/pt unknown
- 2017-06-01 US US15/611,416 patent/US10160800B2/en active Active
-
2018
- 2018-10-25 US US16/170,468 patent/US10889639B2/en active Active
- 2018-11-22 IL IL263243A patent/IL263243A/en unknown
- 2018-11-29 PH PH12018502538A patent/PH12018502538A1/en unknown
- 2018-11-30 CL CL2018003438A patent/CL2018003438A1/es unknown
- 2018-12-19 ZA ZA2018/08582A patent/ZA201808582B/en unknown
- 2018-12-21 CO CONC2018/0014010A patent/CO2018014010A2/es unknown
- 2018-12-28 EC ECSENADI201896095A patent/ECSP18096095A/es unknown
-
2020
- 2020-12-03 US US17/111,159 patent/US11560424B2/en active Active
-
2022
- 2022-01-05 CY CY20221100010T patent/CY1124896T1/el unknown
- 2022-05-19 JP JP2022082099A patent/JP2022110117A/ja active Pending
-
2023
- 2023-01-20 US US18/099,671 patent/US20230331830A1/en active Pending
-
2024
- 2024-01-31 AU AU2024200601A patent/AU2024200601A1/en active Pending
- 2024-06-27 JP JP2024103562A patent/JP2024123247A/ja active Pending
-
2025
- 2025-01-16 US US19/025,554 patent/US20250263477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527194A5 (OSRAM) | ||
| AU2022252753B2 (en) | ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF | |
| KR101629365B1 (ko) | 항원 결합성 단백질 | |
| CN112424223B (zh) | 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途 | |
| JP7078552B2 (ja) | α－シヌクレインに対する抗体およびその使用 | |
| CN104619724B (zh) | 识别α-突触核蛋白的人源化抗体 | |
| EP3261720B1 (en) | Antibodies to tau and uses thereof | |
| JP7045724B2 (ja) | 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途 | |
| KR102263812B1 (ko) | a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도 | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2017536354A5 (OSRAM) | ||
| TW201018482A (en) | Novel treatment | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP6808611B2 (ja) | Ｆｃγ受容体ＩＩＢおよびＦｃε受容体に対する新規の抗体 | |
| JP2018529635A5 (OSRAM) | ||
| JP2021518761A (ja) | 配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法 | |
| CN116249717A (zh) | 识别分拣蛋白的抗体 | |
| CA3242070A1 (en) | Antibodies recognizing sortilin | |
| JP2018529672A5 (OSRAM) | ||
| KR20250019593A (ko) | 항체 및 이를 포함하는 면역질환 치료용 약학적 조성물 | |
| CA3236199A1 (en) | Anti-amyloid beta antibodies and methods of using the same | |
| CN120882746A (zh) | 结合至nkg2a和pd-l1的药剂及其用途 | |
| TW202544031A (zh) | 抗tigit/抗pd-l1雙特異性抗體及其用途 | |
| TH1801007500A (th) | แอนติบอดีต่อแอลฟ่า-ซินนิวคลีอินและการใช้ของสารนี้ |